Fragmin FDA Approval History
FDA Approved: Yes (First approved December 22, 1994)
Brand name: Fragmin
Generic name: dalteparin sodium
Dosage form: Injection
Company: Pfizer Inc.
Treatment for: Heart Attack, Angina, Deep Vein Thrombosis, Venous Thromboembolism
Fragmin (dalteparin sodium) is a low molecular weight heparin (LMWH) indicated for:
- Prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction
- Prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery or medical patients with severely restricted mobility during acute illness
- Extended treatment of symptomatic venous thromboembolism (VTE) to reduce the recurrence in adult patients with cancer. In these patients, the Fragmin therapy begins with the initial VTE treatment and continues for six months
- Treatment of symptomatic venous thromboembolism (VTE) to reduce the recurrence in pediatric patients 1 month of age and older
Development Timeline for Fragmin
|May 16, 2019||FDA Approves Fragmin (dalteparin sodium) as First Anticoagulant for Venous Thromboembolism in Pediatric Patients|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.